This opportunity is no longer accepting applications.
grant PAR-23-274

Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

This grant opportunity invites applications to conduct phase 1 and phase 1b/2a clinical trials together, simplifying early-stage testing of new drug treatments for Alzheimer's and related dementias. These treatments, which can be small molecules or biologics, should target non-amyloid/non-tau mechanisms and aim to improve cognitive or neuropsychiatric symptoms in patients at various stages of …

The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for Alzheimer's disease (AD)…

Funding Source

Agency: National Institutes of Health
Sub-agency: National Institute on Aging
Program: SBIR

Dates

Open for Submission: August 23, 2023
Submission Deadline: November 19, 2026
Opportunity Released: August 23, 2023
Application Window Closes: November 19, 2026

Supporting links

Secure Grant Funding 10x Faster

Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.

Already have an account? Sign In

Trusted by 500+ Happy Customers

Get opportunities sent to your inbox

The latest grant news and insights from our experts.

Save this opportunity and explore more

Share Opportunity

Share this opportunity with others.
Anyone with this link can view the opportunity details.